Microglia in brain aging: An overview of recent basic science and clinical research developments

Abstract

Aging is characterized by progressive degeneration of tissues and organs, and it is positively associated with an increased mortality rate. The brain, as one of the most significantly affected organs, experiences age-related changes, including abnormal neuronal activity, dysfunctional calcium homeostasis, dysregulated mitochondrial function, and increased levels of reactive oxygen species. These changes collectively contribute to cognitive deterioration. Aging is also a key risk factor for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. For many years, neurodegenerative disease investigations have primarily focused on neurons, with less attention given to microglial cells. However, recently, microglial homeostasis has emerged as an important mediator in neurological disease pathogenesis. Here, we provide an overview of brain aging from the perspective of the microglia. In doing so, we present the current knowledge on the correlation between brain aging and the microglia, summarize recent progress of investigations about the microglia in normal aging, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and then discuss the correlation between the senescent microglia and the brain, which will culminate with a presentation of the molecular complexity involved in the microglia in brain aging with suggestions for healthy aging.

Keywords

microglia / brain aging / Alzheimer's disease / Parkinson's disease / Huntington's disease

Fundings

This work was supported by the Operating Grant to Chongqing Key Laboratory of Neurodegenerative Diseases (Grant No. 1000013) and the Plan for High-level Talent Introduction (Grant No. 2000055).

Acknowledgments

None.

References

[1] López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging[J]. Cell, 2013, 153(6): 1194-1217. doi: 10.1016/j.cell.2013.05.039

[2] Department of Economic and Social Affairs. World population ageing 2020 highlights[EB/OL]. [2022-10-01]. https://www.un.org/development/desa/pd/news/world-population-ageing-2020-highlights/.

[3] MacDonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes[J]. Cell, 1993, 72(6): 971-983. doi: 10.1016/0092-8674(93)90585-E

[4] Olde Rikkert MGM, Melis RJF, Cohen AA, et al. Why illness is more important than disease in old age[J]. Age Ageing, 2022, 51(1): afab267. doi: 10.1093/ageing/afab267

[5] Mattson MP, Arumugam TV. Hallmarks of brain aging: adaptive and pathological modification by metabolic states[J]. Cell Metab, 2018, 27(6): 1176-1199. doi: 10.1016/j.cmet.2018.05.011

[6] Moca EN, Lecca D, Hope KT, et al. Microglia drive pockets of neuroinflammation in middle age[J]. J Neurosci, 2022, 42(19): 3896-3918. doi: 10.1523/JNEUROSCI.1922-21.2022

[7] Spiteri AG, Wishart CL, Pamphlett R, et al. Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function[J]. Acta Neuropathol, 2022, 143(2): 179-224. doi: 10.1007/s00401-021-02384-2

[8] Zhao J, Ren T, Li X, et al. Research progress on the role of microglia membrane proteins or receptors in neuroinflammation and degeneration[J]. Front Cell Neurosci, 2022, 16: 831977. doi: 10.3389/fncel.2022.831977

[9] Silvin A, Uderhardt S, Piot C, et al. Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration[J]. Immunity, 2022, 55(8): 1448-1465.e6. doi: 10.1016/j.immuni.2022.07.004

[10] Frost JL, Schafer DP. Microglia: architects of the developing nervous system[J]. Trends Cell Biol, 2016, 26(8): 587-597. doi: 10.1016/j.tcb.2016.02.006

[11] Kierdorf K, Erny D, Goldmann T, et al. Microglia emerge from erythromyeloid precursors via Pu. 1- and Irf8-dependent pathways[J]. Nat Neurosci, 2013, 16(3): 273-280. doi: 10.1038/nn.3318

[12] Gomez Perdiguero E, Klapproth K, Schulz C, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors[J]. Nature, 2015, 518(7540): 547-551. doi: 10.1038/nature13989

[13] Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages[J]. Science, 2010, 330(6005): 841-845. doi: 10.1126/science.1194637

[14] Réu P, Khosravi A, Bernard S, et al. The lifespan and turnover of microglia in the human brain[J]. Cell Rep, 2017, 20(4): 779-784. doi: 10.1016/j.celrep.2017.07.004

[15] Whalley K. Neuronal neighbours tune microglial identity[J]. Nat Rev Neurosci, 2022, 23(10): 582-583. doi: 10.1038/S41583-022-00632-2

[16] Yu Z, Fang X, Liu W, et al. Microglia regulate blood-brain barrier integrity via MiR-126a-5p/MMP9 Axis during inflammatory demyelination[J]. Adv Sci (Weinh), 2022, 9(24): 2105442. doi: 10.1002/advs.202105442

[17] Smith BC, Tinkey RA, Shaw BC, et al. Targetability of the neurovascular unit in inflammatory diseases of the central nervous system[J]. Immunol Rev, 2022, 311(1): 39-49. doi: 10.1111/imr.13121

[18] Du Y, Brennan FH, Popovich PG, et al. Microglia maintain the normal structure and function of the hippocampal astrocyte network[J]. GLIA, 2022, 70(7): 1359-1379. doi: 10.1002/glia.24179

[19] Santos EN, Fields RD. Regulation of myelination by microglia[J]. Sci Adv, 2021, 7(50): eabk1131. doi: 10.1126/sciadv.abk1131

[20] Nguyen PT, Dorman LC, Pan S, et al. Microglial remodeling of the extracellular matrix promotes synapse plasticity[J]. Cell, 2020, 182(2): 388-403.e15. doi: 10.1016/j.cell.2020.05.050

[21] Weinhard L, di Bartolomei G, Bolasco G, et al. Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction[J]. Nat Commun, 2018, 9(1): 1228. doi: 10.1038/s41467-018-03566-5

[22] Boche D, Gordon MN. Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease[J]. Alzheimers Dement, 2022, 18(2): 360-376. doi: 10.1002/alz.12389

[23] Schwabenland M, Brück W, Priller J, et al. Analyzing microglial phenotypes across neuropathologies: a practical guide[J]. Acta Neuropathol, 2021, 142(6): 923-936. doi: 10.1007/s00401-021-02370-8

[24] Nguyen HM, Grössinger EM, Horiuchi M, et al. Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia[J]. GLIA, 2017, 65(1): 106-121. doi: 10.1002/glia.23078

[25] Ransohoff RM. A polarizing question: do M1 and M2 microglia exist?[J]. Nat Neurosci, 2016, 19(8): 987-991. doi: 10.1038/nn.4338

[26] Zhou R, Qian S, Cho WCS, et al. Microbiota-microglia connections in age-related cognition decline[J]. Aging Cell, 2022, 21(5): e13599. doi: 10.1111/ACEL.13599

[27] Mitra S, Banik A, Saurabh S, et al. Neuroimmunometabolism: a new pathological nexus underlying neurodegenerative disorders[J]. J Neurosci, 2022, 42(10): 1888-1907. doi: 10.1523/JNEUROSCI.0998-21.2022

[28] Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease[J]. Nat Rev Neurol, 2019, 15(10): 565-581. doi: 10.1038/s41582-019-0244-7

[29] de Paiva Lopes K, Snijders GJL, Humphrey J, et al. Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies[J]. Nat Genet, 2022, 54(1): 4-17. doi: 10.1038/s41588-021-00976-y

[30] Shahidehpour RK, Higdon RE, Crawford NG, et al. Dystrophic microglia are associated with neurodegenerative disease and not healthy aging in the human brain[J]. Neurobiol Aging, 2021, 99: 19-27. doi: 10.1016/j.neurobiolaging.2020.12.003

[31] Ohm DT, Fought AJ, Martersteck A, et al. Accumulation of neurofibrillary tangles and activated microglia is associated with lower neuron densities in the aphasic variant of Alzheimer's disease[J]. Brain Pathol, 2021, 31(1): 189-204. doi: 10.1111/bpa.12902

[32] Cárdenas-Tueme M, Trujillo-Villarreal LÁ, Ramírez-Amaya V, et al. Fornix volumetric increase and microglia morphology contribute to spatial and recognition-like memory decline in ageing male mice[J]. NeuroImage, 2022, 252: 119039. doi: 10.1016/j.neuroimage.2022.119039

[33] Lopes KO, Sparks DL, Streit WJ. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity[J]. GLIA, 2008, 56(10): 1048-1060. doi: 10.1002/glia.20678

[34] Fernández-Mendívil C, Luengo E, Trigo-Alonso P, et al. Protective role of microglial HO-1 blockade in aging: implication of iron metabolism[J]. Redox Biol, 2021, 38: 101789. doi: 10.1016/j.redox.2020.101789

[35] Ko CJ, Gao SL, Lin TK, et al. Ferroptosis as a major factor and therapeutic target for neuroinflammation in Parkinson's disease[J]. Biomedicines, 2021, 9(11): 1679. doi: 10.3390/biomedicines9111679

[36] Kenkhuis B, Somarakis A, de Haan L, et al. Iron loading is a prominent feature of activated microglia in Alzheimer's disease patients[J]. Acta Neuropathol Commun, 2021, 9(1): 27. doi: 10.1186/s40478-021-01126-5

[37] Marschallinger J, Iram T, Zardeneta M, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain[J]. Nat Neurosci, 2020, 23(2): 194-208. doi: 10.1038/s41593-019-0566-1

[38] Elmore MRP, Hohsfield LA, Kramár EA, et al. Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice[J]. Aging Cell, 2018, 17(6): e12832. doi: 10.1111/acel.12832

[39] Niraula A, Sheridan JF, Godbout JP. Microglia priming with aging and stress[J]. Neuropsychopharmacology, 2017, 42(1): 318-333. doi: 10.1038/npp.2016.185

[40] Hu Y, Fryatt GL, Ghorbani M, et al. Replicative senescence dictates the emergence of disease-associated microglia and contributes to Aβ pathology[J]. Cell Rep, 2021, 35(10): 109228. doi: 10.1016/j.celrep.2021.109228

[41] Safaiyan S, Kannaiyan N, Snaidero N, et al. Age-related myelin degradation burdens the clearance function of microglia during aging[J]. Nat Neurosci, 2016, 19(8): 995-998. doi: 10.1038/nn.4325

[42] Gabandé-Rodríguez E, Keane L, Capasso M. Microglial phagocytosis in aging and Alzheimer's disease[J]. J Neurosci Res, 2020, 98(2): 284-298. doi: 10.1002/jnr.24419

[43] Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation[J]. Nature, 2016, 539(7628): 180-186. doi: 10.1038/nature20411

[44] Olah M, Patrick E, Villani AC, et al. A transcriptomic atlas of aged human microglia[J]. Nat Commun, 2018, 9(1): 539. doi: 10.1038/s41467-018-02926-5

[45] Patel T, Carnwath TP, Wang X, et al. Transcriptional landscape of human microglia implicates age, sex, and APOE-related immunometabolic pathway perturbations[J]. Aging Cell, 2022, 21(5): e13606. doi: 10.1111/ACEL.13606

[46] Brites D. Regulatory function of microRNAs in microglia[J]. GLIA, 2020, 68(8): 1631-1642. doi: 10.1002/glia.23846

[47] Gong H, Chen H, Xiao P, et al. miR-146a impedes the anti-aging effect of AMPK via NAMPT suppression and NAD+/SIRT inactivation[J]. Sig Transduct Target Ther, 2022, 7(1): 66. doi: 10.1038/s41392-022-00886-3

[48] Liang C, Zou T, Zhang M, et al. MicroRNA-146a switches microglial phenotypes to resist the pathological processes and cognitive degradation of Alzheimer's disease[J]. Theranostics, 2021, 11(9): 4103-4121. doi: 10.7150/thno.53418

[49] Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 53. doi: 10.1186/s13046-019-1059-5

[50] Bazrgar M, Khodabakhsh P, Prudencio M, et al. The role of microRNA-34 family in Alzheimer's disease: a potential molecular link between neurodegeneration and metabolic disorders[J]. Pharmacol Res, 2021, 172: 105805. doi: 10.1016/j.phrs.2021.105805

[51] Srinivasan AR, Tran TT, Bonini NM. Loss of miR-34 in Drosophila dysregulates protein translation and protein turnover in the aging brain[J]. Aging Cell, 2022, 21(3): e13559. doi: 10.1111/ACEL.13559

[52] Kennerdell JR, Liu N, Bonini NM. MiR-34 inhibits polycomb repressive complex 2 to modulate chaperone expression and promote healthy brain aging[J]. Nat Commun, 2018, 9(1): 4188. doi: 10.1038/s41467-018-06592-5

[53] Fenn AM, Smith KM, Lovett-Racke AE, et al. Increased micro-RNA 29b in the aged brain correlates with the reduction of insulin-like growth factor-1 and fractalkine ligand[J]. Neurobiol Aging, 2013, 34(12): 2748-2758. doi: 10.1016/j.neurobiolaging.2013.06.007

[54] Schmidt MF, Gan ZY, Komander D, et al. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities[J]. Cell Death Differ, 2021, 28(2): 570-590. doi: 10.1038/s41418-020-00706-7

[55] Hansson O. Biomarkers for neurodegenerative diseases[J]. Nat Med, 2021, 27(6): 954-963. doi: 10.1038/s41591-021-01382-x

[56] GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2019, 18(5): 459-480. doi: 10.1016/S1474-4422(18)30499-X

[57] Brodaty H, Breteler MMB, Dekosky ST, et al. The world of dementia beyond 2020[J]. J Am Geriatr Soc, 2011, 59(5): 923-927. doi: 10.1111/j.1532-5415.2011.03365.x

[58] Bogár F, Fülöp L, Penke B. Novel therapeutic target for prevention of neurodegenerative diseases: modulation of neuroinflammation with Sig-1R ligands[J]. Biomolecules, 2022, 12(3): 363. doi: 10.3390/biom12030363

[59] Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease[J]. Nat Rev Dis Primers, 2021, 7(1): 33. doi: 10.1038/s41572-021-00269-y

[60] 2021 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2021, 17(3): 327-406.

[61] Taipa R, Ferreira V, Brochado P, et al. Inflammatory pathology markers (activated microglia and reactive astrocytes) in early and late onset Alzheimer disease: a post mortem study[J]. Neuropathol Appl Neurobiol, 2018, 44(3): 298-313. doi: 10.1111/nan.12445

[62] Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?[J]. Nat Rev Neurol, 2021, 17(3): 157-172. doi: 10.1038/s41582-020-00435-y

[63] Pascoal TA, Benedet AL Ashton NJ, et al., Microglial activation and tau propagate jointly across Braak stages[J]. Nat Med, 2021, 27(9): 1592-1599. doi: 10.1038/s41591-021-01456-w

[64] Clayton K, Delpech JC, Herron S, et al. Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model[J]. Mol Neurodegener, 2021, 16(1): 18. doi: 10.1186/s13024-021-00440-9

[65] Wood H. Alzheimer disease: evidence for trans-synaptic and exo-synaptic tau propagation in Alzheimer disease[J]. Nat Rev Neurol, 2015, 11(12): 665. doi: 10.1038/nrneurol.2015.205

[66] d'Errico P, Ziegler-Waldkirch S, Aires V, et al. Microglia contribute to the propagation of Aβ into unaffected brain tissue[J]. Nat Neurosci, 2022, 25(1): 20-25. doi: 10.1038/s41593-021-00951-0

[67] McFarland KN, Chakrabarty P. Microglia in Alzheimer's disease: a key player in the transition between homeostasis and pathogenesis[J]. Neurotherapeutics, 2022, 19(1): 186-208. doi: 10.1007/s13311-021-01179-3

[68] Gratuze M, Chen Y, Parhizkar S, et al. Activated microglia mitigate Aβ-associated tau seeding and spreading[J]. J Exp Med, 2021, 218(8): e20210542. doi: 10.1084/jem.20210542

[69] Hamelin L, Lagarde J, Dorothée G, et al. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging[J]. Brain, 2016, 139(Pt 4): 1252-1264. https://academic.oup.com/brain/article/139/4/1252/2464345

[70] Zhang L, Hu K, Shao T, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging[J]. Acta Pharm Sin B, 2021, 11(2): 373-393. doi: 10.1016/j.apsb.2020.08.006

[71] Hamelin L, Lagarde J, Dorothée G, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease[J]. Brain, 2018, 141(6): 1855-1870. doi: 10.1093/brain/awy079

[72] Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's Disease[J]. Cell, 2017, 169(7): 1276-1290.e17. doi: 10.1016/j.cell.2017.05.018

[73] Lempriere S. TREM2 response occurs early in amyloid cascade[J]. Nat Rev Neurol, 2022, 18(5): 251.

[74] Gratuze M, Leyns CEG, Sauerbeck AD, et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration[J]. J Clin Invest, 2020, 130(9): 4954-4968. doi: 10.1172/JCI138179

[75] Kim B, Suh E, Nguyen AT, et al. TREM2 risk variants are associated with atypical Alzheimer's disease[J]. Acta Neuropathol, 2022, 144(6): 1085-1102. doi: 10.1007/s00401-022-02495-4

[76] Yeh FL, Hansen DV, Sheng M. TREM2, microglia, and neurodegenerative diseases[J]. Trends Mol Med, 2017, 23(6): 512-533. doi: 10.1016/j.molmed.2017.03.008

[77] Roda AR, Serra-Mir G, Montoliu-Gaya L, et al. Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease[J]. Neural Regen Res, 2022, 17(8): 1666-1674. doi: 10.4103/1673-5374.332127

[78] Fan Z, Brooks DJ, Okello A, et al. An early and late peak in microglial activation in Alzheimer's disease trajectory[J]. Brain, 2017, 140(3): 792-803. https://pubmed.ncbi.nlm.nih.gov/28122877/

[79] Bloem BR, Okun MS, Klein C. Parkinson's disease[J]. Lancet, 2021, 397(10291): 2284-2303. doi: 10.1016/S0140-6736(21)00218-X

[80] Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment[J]. Nat Rev Dis Primers, 2021, 7(1): 47. doi: 10.1038/s41572-021-00280-3

[81] Raza C, Anjum R, Shakeel NUA. Parkinson's disease: mechanisms, translational models and management strategies[J]. Life Sci, 2019, 226: 77-90. doi: 10.1016/j.lfs.2019.03.057

[82] Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease[J]. Neurobiol Dis, 2006, 21(2): 404-412. doi: 10.1016/j.nbd.2005.08.002

[83] Duffy MF, Collier TJ, Patterson JR, et al. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration[J]. J Neuroinflammation, 2018, 15(1): 129. doi: 10.1186/s12974-018-1171-z

[84] Lavisse S, Goutal S, Wimberley C, et al. Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging[J]. Parkinsonism Relat Disord, 2021, 82: 29-36. doi: 10.1016/j.parkreldis.2020.11.011

[85] Li Y, Xia Y, Yin S, et al. Targeting microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 inflammasome axis in Parkinson's disease[J]. Front Immunol, 2021, 12: 719807. doi: 10.3389/fimmu.2021.719807

[86] Scheiblich H, Bousset L, Schwartz S, et al. Microglial NLRP3 inflammasome activation upon TLR2 and TLR5 ligation by distinct α-synuclein assemblies[J]. J Immunol, 2021, 207(8): 2143-2154. doi: 10.4049/jimmunol.2100035

[87] Bido S, Muggeo S, Massimino L, et al. Microglia-specific overexpression of α-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity[J]. Nat Commun, 2021, 12(1): 6237. doi: 10.1038/s41467-021-26519-x

[88] Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease[J]. Ageing Res Rev, 2018, 45: 53-61. doi: 10.1016/j.arr.2018.04.004

[89] Bi M, Feng L, He J, et al. Emerging insights between gut microbiome dysbiosis and Parkinson's disease: pathogenic and clinical relevance[J]. Ageing Res Rev, 2022, 82: 101759. doi: 10.1016/j.arr.2022.101759

[90] Wang Q, Luo Y, Ray Chaudhuri K, et al. The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options[J]. Brain, 2021, 144(9): 2571-2593. doi: 10.1093/brain/awab156

[91] Wang W, Jiang S, Xu C, et al. Interactions between gut microbiota and Parkinson's disease: the role of microbiota-derived amino acid metabolism[J]. Front Aging Neurosci, 2022, 14: 976316. doi: 10.3389/fnagi.2022.976316

[92] Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease[J]. Cell, 2016, 167(6): 1469-1480.e12. doi: 10.1016/j.cell.2016.11.018

[93] Rai SN, Singh P. Advancement in the modelling and therapeutics of Parkinson's disease[J]. J Chem Neuroanat, 2020, 104: 101752. doi: 10.1016/j.jchemneu.2020.101752

[94] Rai SN, Singh P, Varshney R, et al. Promising drug targets and associated therapeutic interventions in Parkinson's disease[J]. Neural Regen Res, 2021, 16(9): 1730-1739. doi: 10.4103/1673-5374.306066

[95] Rai SN, Chaturvedi VK, Singh P, et al. Mucuna pruriens in Parkinson's and in some other diseases: recent advancement and future prospective[J]. 3 Biotech, 2020, 10(12): 522. doi: 10.1007/s13205-020-02532-7

[96] Rai SN, Birla H, Singh SS, et al. Mucuna pruriens protects against MPTP intoxicated neuroinflammation in Parkinson's disease through NF-κB/pAKT signaling pathways[J]. Front Aging Neurosci, 2017, 9: 421. doi: 10.3389/fnagi.2017.00421

[97] Rai SN, Zahra W, Singh SS, et al. Anti-inflammatory activity of ursolic acid in MPTP-induced parkinsonian mouse model[J]. Neurotox Res, 2019, 36(3): 452-462. doi: 10.1007/s12640-019-00038-6

[98] Singh SS, Rai SN, Birla H, et al. Neuroprotective effect of chlorogenic acid on mitochondrial dysfunction-mediated apoptotic death of DA neurons in a Parkinsonian mouse model[J]. Oxid Med Cell Longev, 2020, 2020: 6571484. doi: 10.1155/2020/6571484

[99] Prakash J, Chouhan S, Yadav SK, et al. Withania somnifera alleviates parkinsonian phenotypes by inhibiting apoptotic pathways in dopaminergic neurons[J]. Neurochem Res, 2014, 39(12): 2527-2536. doi: 10.1007/s11064-014-1443-7

[100] Wang Y, Tong Q, Ma S, et al. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota[J]. Sig Transduct Target Ther, 2021, 6(1): 77. doi: 10.1038/s41392-020-00456-5

[101] Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics[J]. Nat Rev Neurol, 2014, 10(4): 204-216. doi: 10.1038/nrneurol.2014.24

[102] Behl T, Kaur G, Sehgal A, et al. Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: pathophysiological and therapeutic perspectives[J]. Int J Mol Sci, 2021, 22(3): 1413. doi: 10.3390/ijms22031413

[103] Rocha NP, Charron O, Latham LB, et al. Microglia activation in basal ganglia is a late event in Huntington disease pathophysiology[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8(3): e984. doi: 10.1212/NXI.0000000000000984

[104] Savage JC, St-Pierre MK, Carrier M, et al. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology[J]. J Neuroinflammation, 2020, 17(1): 98. doi: 10.1186/s12974-020-01782-9

[105] Connolly C, Magnusson-Lind A, Lu G, et al. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin[J]. Neuroscience, 2016, 325: 74-88. doi: 10.1016/j.neuroscience.2016.03.031

[106] Goutman SA, Hardiman O, Al-Chalabi A, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis[J]. Lancet Neurol, 2022, 21(5): 480-493. doi: 10.1016/S1474-4422(21)00465-8

[107] Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis[J]. J Neurol, 2020, 267(4): 944-953. doi: 10.1007/s00415-019-09652-y

[108] Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis[J]. N Engl J Med, 2017, 377(2): 162-172. doi: 10.1056/NEJMra1603471

[109] Quek H, Cuní-López C, Stewart R, et al. ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression[J]. J Neuroinflammation, 2022, 19(1): 58. doi: 10.1186/s12974-022-02421-1

[110] Dols-Icardo O, Montal V, Sirisi S, et al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(5): e829. doi: 10.1212/NXI.0000000000000829

[111] Alshikho MJ, Zürcher NR, Loggia ML, et al. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis[J]. Neurology, 2016, 87(24): 2554-2561. doi: 10.1212/WNL.0000000000003427

[112] Brettschneider J, Toledo JB, Van Deerlin VM, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis[J]. PLoS One, 2012, 7(6): e39216. doi: 10.1371/journal.pone.0039216

[113] Paolicelli RC, Jawaid A, Henstridge CM, et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss[J]. Neuron, 2017, 95(2): 297-308.e6. doi: 10.1016/j.neuron.2017.05.037

[114] Reyes-Leiva D, Dols-Icardo O, Sirisi S, et al. Pathophysiological underpinnings of extra-motor neurodegeneration in amyotrophic lateral sclerosis: new insights from biomarker studies[J]. Front Neurol, 2022, 12: 750543. doi: 10.3389/fneur.2021.750543

[115] Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology[J]. Nat Rev Mol Cell Biol, 2014, 15(7): 482-496. doi: 10.1038/nrm3823

[116] Childs BG, Gluscevic M, Baker DJ, et al. Senescent cells: an emerging target for diseases of ageing[J]. Nat Rev Drug Discov, 2017, 16(10): 718-735. doi: 10.1038/nrd.2017.116

[117] Si Z, Sun L, Wang X. Evidence and perspectives of cell senescence in neurodegenerative diseases[J]. Biomed Pharmacother, 2021, 137: 111327. doi: 10.1016/j.biopha.2021.111327

[118] Goldmann T, Wieghofer P, Jordão MJC, et al. Origin, fate and dynamics of macrophages at central nervous system interfaces[J]. Nat Immunol, 2016, 17(7): 797-805. doi: 10.1038/ni.3423

[119] Spittau B. Aging microglia-phenotypes, functions and implications for age-related neurodegenerative diseases[J]. Front Aging Neurosci, 2017, 9: 194. doi: 10.3389/fnagi.2017.00194

[120] Davies DS, Ma J, Jegathees T, et al. Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer's disease[J]. Brain Pathol, 2017, 27(6): 795-808. doi: 10.1111/bpa.12456

[121] Mrdjen D, Pavlovic A, Hartmann FJ, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease[J]. Immunity, 2018, 48(3): 599. doi: 10.1016/j.immuni.2018.02.014

[122] Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path forward[J]. Cell, 2019, 179(4): 813-827. doi: 10.1016/j.cell.2019.10.005

[123] Baker DJ, Petersen RC. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives[J]. J Clin Invest, 2018, 128(4): 1208-1216. doi: 10.1172/JCI95145

[124] Wendimu MY, Hooks SB. Microglia phenotypes in aging and neurodegenerative diseases[J]. Cells, 2022, 11(13). doi: 10.3390/cells11132091

[125] Kiss T, Nyúl-Tóth Á, DelFavero J, et al. Spatial transcriptomic analysis reveals inflammatory foci defined by senescent cells in the white matter, hippocampi and cortical grey matter in the aged mouse brain[J]. Geroscience, 2022, 44(2): 661-681. doi: 10.1007/s11357-022-00521-7

[126] Hammond TR, Dufort C, Dissing-Olesen L, et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes[J]. Immunity, 2019, 50(2): 253-271.e6. doi: 10.1016/j.immuni.2018.11.004

[127] Ogrodnik M, Evans SA, Fielder E, et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice[J]. Aging Cell, 2021, 20(2): e13296. https://pubmed.ncbi.nlm.nih.gov/33470505/

[128] Bussian TJ, Aziz A, Meyer CF, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline[J]. Nature, 2018, 562(7728): 578-582. doi: 10.1038/s41586-018-0543-y